These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20236614)

  • 1. Myocardial effects of VDR activators in renal failure.
    Mizobuchi M; Nakamura H; Tokumoto M; Finch J; Morrissey J; Liapis H; Slatopolsky E
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):188-92. PubMed ID: 20236614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.
    Panizo S; Barrio-Vázquez S; Naves-Díaz M; Carrillo-López N; Rodríguez I; Fernández-Vázquez A; Valdivielso JM; Thadhani R; Cannata-Andía JB
    Nephrol Dial Transplant; 2013 Nov; 28(11):2735-44. PubMed ID: 24013683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of calcitriol and paricalcitol on renal fibrosis in CKD.
    Martínez-Arias L; Panizo S; Alonso-Montes C; Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; García Gil-Albert C; Palomo-Antequera C; Fernández-Martín JL; Ruiz-Torres MP; Dusso AS; Carrillo-López N; Cannata-Andía JB; Naves-Díaz M
    Nephrol Dial Transplant; 2021 Apr; 36(5):793-803. PubMed ID: 33416889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis.
    Panizo S; Carrillo-López N; Naves-Díaz M; Solache-Berrocal G; Martínez-Arias L; Rodrigues-Díez RR; Fernández-Vázquez A; Martínez-Salgado C; Ruiz-Ortega M; Dusso A; Cannata-Andía JB; Rodríguez I
    Nephrol Dial Transplant; 2017 Nov; 32(11):1831-1840. PubMed ID: 28460073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.
    Czaya B; Seeherunvong W; Singh S; Yanucil C; Ruiz P; Quiroz Y; Grabner A; Katsoufis C; Swaminathan S; Abitbol C; Rodriguez-Iturbe B; Faul C; Freundlich M
    Am J Hypertens; 2019 Jan; 32(1):34-44. PubMed ID: 30329020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy.
    Mirkovic K; Frenay AS; van den Born J; van Goor H; Navis G; de Borst MH;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1293-1301. PubMed ID: 26311058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.
    Wu-Wong JR; Kawai M; Chen YW; Nakane M
    Br J Pharmacol; 2011 Sep; 164(2b):551-60. PubMed ID: 21557735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
    Andress D
    Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
    Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease.
    Rayego-Mateos S; Morgado-Pascual JL; Valdivielso JM; Sanz AB; Bosch-Panadero E; Rodrigues-Díez RR; Egido J; Ortiz A; González-Parra E; Ruiz-Ortega M
    J Am Soc Nephrol; 2020 Sep; 31(9):2026-2042. PubMed ID: 32631974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.
    Freundlich M; Quiroz Y; Zhang Z; Zhang Y; Bravo Y; Weisinger JR; Li YC; Rodriguez-Iturbe B
    Kidney Int; 2008 Dec; 74(11):1394-402. PubMed ID: 18813285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.
    Freundlich M; Li YC; Quiroz Y; Bravo Y; Seeherunvong W; Faul C; Weisinger JR; Rodriguez-Iturbe B
    Am J Hypertens; 2014 May; 27(5):720-6. PubMed ID: 24072555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac effect of vitamin D receptor modulators in uremic rats.
    Mizobuchi M; Ogata H; Yamazaki-Nakazawa A; Hosaka N; Kondo F; Koiwa F; Kinugasa E; Shibata T
    J Steroid Biochem Mol Biol; 2016 Oct; 163():20-7. PubMed ID: 27072785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
    Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
    J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction.
    Bae S; Singh SS; Yu H; Lee JY; Cho BR; Kang PM
    J Appl Physiol (1985); 2013 Apr; 114(8):979-87. PubMed ID: 23429874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
    Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
    Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
    Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
    Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D receptor activation and prevention of arterial ageing.
    Cozzolino M; Stucchi A; Rizzo MA; Soldati L; Cusi D; Ciceri P; Brenna I; Elli F; Gallieni M
    Nutr Metab Cardiovasc Dis; 2012 Jul; 22(7):547-52. PubMed ID: 22633189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.